{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:53:20Z","timestamp":1755798800421,"version":"3.44.0"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,19]]},"DOI":"10.7759\/cureus.90484","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T13:30:18Z","timestamp":1755610218000},"source":"Crossref","is-referenced-by-count":0,"title":["Nivolumab-Induced Fasciitis Mimicking Scleroderma: A Diagnostic Challenge"],"prefix":"10.7759","author":[{"given":"Rida","family":"Jannat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kshatri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupak","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma","volume":"37","author":"Mahoney KM","year":"2015","unstructured":"Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma. Clin Ther. 2015, 37:764-82. 10.1016\/j.clinthera.2015.02.018","journal-title":"Clin Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00246-z","article-title":"Immune checkpoint inhibitor-associated scleroderma-like syndrome: a report of a pembrolizumab-induced \"eosinophilic fasciitis-like\" case and a review of the literature","volume":"7","author":"Salamaliki C","year":"2020","unstructured":"Salamaliki C, Solomou EE, Liossis SC. Immune checkpoint inhibitor-associated scleroderma-like syndrome: a report of a pembrolizumab-induced \"eosinophilic fasciitis-like\" case and a review of the literature. Rheumatol Ther. 2020, 7:1045-52. 10.1007\/s40744-020-00246-z","journal-title":"Rheumatol Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0508","article-title":"Eosinophilic fasciitis following checkpoint inhibitor therapy: four cases and a review of literature","volume":"25","author":"Chan KK","year":"2020","unstructured":"Chan KK, Magro C, Shoushtari A, et al.. Eosinophilic fasciitis following checkpoint inhibitor therapy: four cases and a review of literature. Oncologist. 2020, 25:140-9. 10.1634\/theoncologist.2019-0508","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaa001","article-title":"Nivolumab-induced eosinophilic fasciitis: a case report","volume":"4","author":"Ollier N","year":"2020","unstructured":"Ollier N, Tournier E, Meyer N, et al.. Nivolumab-induced eosinophilic fasciitis: a case report. Rheumatol Adv Pract. 2020, 4:rkaa001. 10.1093\/rap\/rkaa001","journal-title":"Rheumatol Adv Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/395275-nivolumab-induced-fasciitis-mimicking-scleroderma-a-diagnostic-challenge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T13:30:18Z","timestamp":1755610218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/395275-nivolumab-induced-fasciitis-mimicking-scleroderma-a-diagnostic-challenge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":4,"URL":"https:\/\/doi.org\/10.7759\/cureus.90484","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,19]]}}}